Promising Results of CRS/HIPEC Treatment
| | |

Promising Results of CRS/HIPEC Treatment

A new treatment can lead to good short- and long-term outcomes for patients with mesothelioma. It’s called cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Research results came from the Medical University of Vienna in Austria. They looked at the first 100 mesothelioma patients who had this treatment in their hospital. Advancing Mesothelioma Care Mesothelioma is a rare form of cancer that grows in the lining that covers many of the internal organs of the body. Mesothelioma is caused by exposure to asbestos. There are approximately 2,000 cases of mesothelioma diagnosed in the United States every year. The standard treatment for mesothelioma usually includes surgery, chemotherapy, and radiation. The typical prognosis with standard treatment is survival between one and five years….

Mesothelioma Surgery is Now Much Safer
| |

Mesothelioma Surgery is Now Much Safer

Doctors have made huge improvements on a procedure called cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This is positive news for people for malignant peritoneal mesothelioma. Surgery as a Treatment CRS/HIPEC is a surgery that is used to treat cancers that are found on the surface of organs in the stomach area. This includes malignant peritoneal mesothelioma (MPM). MPM is an aggressive cancer caused by asbestos. The cancer grows on the lining of the abdominal cavity. Symptoms of MPM are usually noticed first in the stomach area. People might feel abdominal pain or swelling, fever, and night sweats. MPM is the second most common form of mesothelioma. The most common type of this cancer is malignant pleural mesothelioma, which grows…